Dr Regu logo Dr ReguClinical Library Browse the Library
Home / Library / PBS Authority Suite / Trulicity PBS Authority
PBS Authority

Trulicity (Dulaglutide)

PBS eligibility — type 2 diabetes · GLP-1 receptor agonist

Field: EndocrineCode: DE-02Updated: June 2026Reference: pbs.gov.au
PBS-listed for type 2 diabetes as add-on therapy — dulaglutide once weekly, no titration. Initiation gate: contraindication/intolerance to an SGLT2 inhibitor, or no clinically meaningful glycaemic response to one. Verify current criteria at pbs.gov.au.

1Eligibility — who qualifies on the PBS

Diagnosis — Type 2 diabetes mellitus — not type 1, LADA, MODY or gestational diabetes.
SGLT2i criterion — Contraindication/intolerance requiring discontinuation of an SGLT2 inhibitor, or no clinically meaningful glycaemic response to one (PBAC, June 2024).
Combination — With at least one of metformin, a sulfonylurea or insulin. Not with another GLP-1 RA, an SGLT2i for diabetes, or a DPP-4i.
Authority — Initiation: Authority Required — phone 1800 888 333 or PBS Online / HPOS. Continuation: Streamlined (no phone call).

2When to choose Trulicity (vs other GLP-1 RAs)

Established CVD — REWIND: ~12% reduction in major CV events across the risk spectrum, including primary prevention.
Renal protection — REWIND: ~15% reduction in a composite renal outcome; no dose adjustment, usable to eGFR 15.
Simpler dosing — No titration — start at the maintenance dose from week 1, unlike semaglutide.
Once-weekly dose — Fixed once-weekly injection. Confirm available strengths at pbs.gov.au.

3Continuation / renewal — document at each renewal

  • Clinical benefit — HbA1c reduction, weight reduction, or improved glycaemic control.
  • No new contraindications, and still on an eligible combination (metformin, a sulfonylurea, or insulin).

Safety

  • Not for type 1 diabetes, LADA or gestational diabetes.
  • MEN2 / medullary thyroid cancer (personal or family history) — class effect.
  • Acute pancreatitis, active or past — withhold; specialist input before any restart.
  • Cease before a planned pregnancy (TGA category B3).

Check / exclude

  • Confirm still on an eligible combination at each renewal.
  • Not with another GLP-1 RA, an SGLT2i for diabetes, or a DPP-4i.
  • Hypoglycaemia risk rises with insulin or a sulfonylurea — consider a dose reduction.
  • Re-verify the current PBS restriction at pbs.gov.au.

DE-02 v1.1 · Reviewed Jun 2026 · Review Dec 2026

For health-professional use. Summary only — not a substitute for the current PBS Schedule or the approved product information. Verify eligibility, restriction level and authority requirements at pbs.gov.au before prescribing. PBS criteria change frequently.